Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth

Journal of Virology

Volumn 74, Issue 19, 2000, Pages 9083-9089

  Liu, D W ^a   Tsao, Y P ^a   Hsieh, C H ^a   Hsieh, J T ^a   Kung, J T ^a   Chiang, C L ^a   Huang, S J ^a   Chen, S L ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; TUMOR REJECTION ANTIGEN; TUMOR VACCINE; VIRUS PROTEIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GROWTH REGULATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH; UTERINE CERVIX CANCER; VIRUS GENE; VIRUS RECOMBINANT; VIRUS VECTOR; WART VIRUS;

ADENOVIRIDAE; ANIMAL; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CERVIX NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENETIC VECTORS; HUMAN; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; SUPPORT, NON-U.S. GOV'T; VACCINES, SYNTHETIC;

EID: 0033798739     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.19.9083-9089.2000     Document Type: Article

References (65)

1. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer
2. Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc
3. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer
4. Pre-existing immunity to adenovirus does not prevent tumor regression following intra-tumoral administration of a vector expressing IL-12 but inhibits virus dissemination
5. Identification of immunogenic regions of the major coat protein of human papillomavirus type 16 that contain type-restricted epitopes
6. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen
7. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16
8. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen
9. Mutational analysis of human papillomavirus type 11 E5a oncoprotein
10. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein
11. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells
12. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector
13. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
14. A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice
15. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: Protective immune responses in rodents
16. High level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: Induction of an MHC-1-restricted CTL response and protection in a murine model
17. Epidemiology of anogenital warts and cancer
18. Immunology of papillomavirus infection
19. Mucosal immunity and protection after intranasal immunisation with a recombinant adenovirus expressing herpes simplex glycoprotein B
20. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector
21. Proliferative T-cell responses to human papillomavirus type 16 E5 are decreased amongst women with high-grade neoplasia
22. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
23. + T cells in major histocompatibility complex class II-deficient mice
24. Role of the human papillomavirus in human cancer
25. The HPV-16 E5 protein: Expression, detection, and stable complex formation with transmembrane proteins in COS cells
26. Adenovirus vectors as recombinant viral vaccines
27. High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: Protection elicited in a murine model
28. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2
29. Detection of E5 oncoprotein in human papillomavirus type 16-positive cervical scrapes using antibodies raised to synthetic peptides
30. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: A preclinical study
31. Suppression of human bladder cancer growth by increased expression of C-CAM-1 gene in an orthotopic model
32. + T cells
33. Human immunodeficiency virus, human papillomavirus, and cervical intraepithelial neoplasia in Nairobi prostitutes
34. Synthesis of INF-γ by CDS+ T cells is preserved in HIV-infected women with HPV-related cervical squamous intraepithelial lesions
35. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
36. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer
37. Mucosal immunization with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice
38. Immunization of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen
39. 'Sero-switch' adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype
40. Anal and cervical abnormality in womenprediction by human papillomavirus tests
41. Skin-associated lymphoid tissue in human immunodeficiency virus-1, human papillomavirus, and herpes simplex virus infections
42. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7
43. Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: Retardation of BPV1 tumor development
44. Human papillomavirus infection in sexually active adolescent females: Prevalence and risk factors
45. Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line
46. A recombinant human adenovirus vaccine against rabies
47. Determinants of squamous intraepithelial lesions (SIL) on Pap smear: The role of HPV infection and of HIV-1-induced immunosuppression. DIANAIDS Collaborative Study Group
48. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins
49. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection
50. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias
51. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes
52. Human papillomavirus infection in women infected with the human immunodeficiency virus
53. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or 'self' antigens induce antitumor immunity in vivo
54. High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection
55. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A
56. Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection
57. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens
58. Induction and measurement of cytotoxic T lymphocyte activity
59. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy
60. Adenovirus-mediated gene transfer for cystic fibrosis: Quantitative evaluation of repeated in vivo vector administration to the hung
61. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy
62. Development and application of adenoviral vectors for gene therapy of cancer
63. Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2(d) mice
64. Germline transmission of a disrupted β2-microglobulin gene produced by homologous recombination in embryonic stem cells
65. Human papillomaviruses